Nerve Biologic Products Market: Developing Innovative Technology


Nerve biologic products include artificial nerve conduit, nerve graft, nerve wraps, or nerve capping devices used for guiding axonal regrowth to facilitate nerve regeneration. These devices are majorly used in clinical treatments for nerve injuries. Nerve biologic products are commonly used for complex suturing, for instance suturing of two ends of a separated nerve that needs rigid process. The scaffold material used for generating nerve biologic products is either from synthetic or biological origin. The nerve biologic products are manufactured from various biocompatible products such as polysialic acid (PSA), collagen type I/III, spider silk fiber, silkworm silk fibroin, chitosan, aragonite, and alginate.

Nerve Biologic Products Market Drivers

Advancements in research and development for developing innovative technology for nerve biologic products are expected to drive growth of the nerve biologic product market. For instance, in February 2015, researchers from the University of Sheffield developed a device, 3D-printed nerve guidance conduit (NGC). NGC is a network of miniature tubes, which guide injured nerve ends towards each other, thereby enabling them to repair naturally. The device uses computer-aided design (CAD), which can be modified for any type of nerve damage or even adapted for joint specific nerves of patient.

Furthermore, in June 2016, Polyganics, a medical device manufacturing company, received the CE mark for Neurocap, its nerve capping device. Neurocap is an absorbable implant for treatment and reduction of symptomatic neuroma in peripheral nerves. The device was cleared for sales in the U.S. in January 2016.

Moreover, U.S. Food and Drug Administration’s (USFDA) clearances for nerve biologic products is projected to increase growth of the market. For instance, in June 2014, Collagen Matrix Inc. received USFDA clearance for its Flexible Collagen Nerve Conduit. Flexible Collagen Nerve Conduit is a resorbable and flexible type I collagen tubular matrix that offers encasement for peripheral nerve injuries as well as shielding of the neural environment.

Nerve Biologic Products Market – Regional Analysis

On the basis of region, the global nerve biologic products market is segmented into North America, Latin America, Europe, Asia Pacific, Middle East, and Africa.

Based on region, North America is expected to hold lead position in the global nerve biologic products market during the forecast period, owing to rising number of peripheral nerve injuries in the U.S. For instance, according to Proceedings of the National Academy of Sciences of the U.S. study in June 2017, over 250,000 people from the U.S. suffers from peripheral nerve injury annually.

Asia Pacific and Europe region is also expected to observe significant growth in the nerve biologic products market. This is attributed to rising awareness of central nervous system disorders and therapeutic treatments through organized conferences. For instance, proceeding to 6th International Conference on Central Nervous System (CNS) Disorder and Therapeutics which is to be held in Paris in November 2018, 7th International Conference on Central Nervous System (CNS) Disorder and Therapeutics is to be held in Japan in June 2019. These conferences mainly discusses on topics such as diseases and disorders of the CNS, neuroimmunological disorders, neurometabolic disorders, brain tumors, and neurosurgery.

You Can Request Sample Copy of Report Before Buying Here

Nerve Biologic Products Market – Key Players

Key players operating in the global nerve biologic products market include, Stryker, AxoGen, Inc., Integra LifeSciences, Collagen Matrix, Inc., Polyganics, Checkpoint Surgical Inc., and TEXAS PHARMACUETICAL PVT LTD.


About Author

Curt Reaves started working for Plains Gazette in 2016. Curt grew up in a small town in northern Iowa. He studied chemistry in college, graduated, and married his wife one month later. He has been a proud Texan for the past 5 years. Curt covers politics and the economy. Previously he wrote for the Washington City Paper, The Hill newspaper, Slate Magazine, and